https://www.********.au/2019/09/30/...osteoarthritis-discovery-is-it-the-real-deal/
Paradigm reports “ground-breaking” osteoarthritis discovery: Is it the real deal?
Tom Richardson | September 30, 2019 9:23am | More on: BNO MSB NXS OPT PAR
The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price could hit a record high this morning after the medical researcher boasted of a “ground breaking” discovery for its drug designed to treat osteoarthritis in the knees.
According to the company its patented drug Zilosul has been shown to inhibit ‘nerve growth factor’ (NGF) in bone cells in knee osteoarthritis patients and thus reduce pain. It reports that its research has been peer reviewed and published in the international scientific journal PLoS One.
The research also supports Paradigm’s conclusions from its recent Phase II clinical trial into the treatment of pain and cartilage degeneration in knees and supports its regulatory submissions to the U.S. healthcare regulator the FDA.
Paradigm will need to run a far larger, more expensive, and clinically comprehensive clinical trial into the drug in order to persuade the FDA of its clinical efficacy.
The biotech also claimed the drug offered a “very attractive commercial opportunity” for ‘big pharma’ to partner with it in funding research and commercialisation. In part it claimed this is because the drug could help meet the need to treat the “opiate addiction” crisis in the US.
If it can strike a partnership deal with “big pharma” this is likely to be a major positive for the business and stock.
All this sounds exciting and Paradigm already has a market value around $488 million despite having no material revenues and expensive drug trials ahead of it. Thankfully it did have around $72 million cash on hand as at June 30, 2019.
As we’re not far from Melbourne Cup Day, Paradigm could be considered one of the ‘favourites’ amongst a field of speccy ASX biotechs looking for eternal glory.
- Forums
- ASX - By Stock
- PAR
- research reports and media
research reports and media, page-163
-
- There are more pages in this discussion • 4,266 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $70.04M |
Open | High | Low | Value | Volume |
20.5¢ | 21.0¢ | 20.0¢ | $153.1K | 752.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 105727 | 20.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
21.0¢ | 143036 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 65788 | 0.200 |
12 | 210704 | 0.195 |
20 | 271889 | 0.190 |
6 | 132240 | 0.185 |
15 | 730784 | 0.180 |
Price($) | Vol. | No. |
---|---|---|
0.205 | 10008 | 2 |
0.210 | 174046 | 7 |
0.215 | 186932 | 7 |
0.220 | 82155 | 7 |
0.225 | 31604 | 3 |
Last trade - 13.43pm 10/10/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
EL8
ELEVATE URANIUM LTD
Murray Hill, MD & CEO
Murray Hill
MD & CEO
SPONSORED BY The Market Online